Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorN/A
Phone+85221213888
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees590
OptionableNot Optionable
Hutchison China MediTech (LON:HCM) Frequently Asked Questions
What is Hutchison China MediTech's stock symbol?
Hutchison China MediTech trades on the London Stock Exchange (LON) under the ticker symbol "HCM."
Has Hutchison China MediTech been receiving favorable news coverage?
Media stories about HCM stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hutchison China MediTech earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Hutchison China MediTech's key competitors?
Some companies that are related to Hutchison China MediTech include Allergy Therapeutics (AGY), Bayer (BAYN), Bayer (BAYN), BEXIMCO PHARMAC/S GDR REGS (BXP), Cathay International (CTI), Dechra Pharmaceuticals (DPH), Eco Animal Health Group (EAH), Futura Medical (FUM), N4 Pharma (N4P), OTSUKA HOLDINGS/ADR (OTSKY), Sanofi (SAN), Sareum (SAR), SINR PHAR/PAR VTG FPD 0.01 (SPH) and Vectura Group (VEC).
Who are Hutchison China MediTech's key executives?
Hutchison China MediTech's management team includes the folowing people:
- Mr. Chi Keung To BSc, ACGI, MBA, Exec. Chairman (Age 66)
- Mr. Christian Hogg BSc, MBA, CEO & Exec. Director (Age 52)
- Mr. Johnny Cheng BEc, CA, CFO & Exec. Director (Age 51)
- Dr. Weiguo Su Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 61)
- Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 66)
How do I buy shares of Hutchison China MediTech?
Shares of HCM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Hutchison China MediTech's stock price today?
One share of HCM stock can currently be purchased for approximately GBX 3,885.
What is Hutchison China MediTech's official website?
How can I contact Hutchison China MediTech?
The company can be reached via phone at +85221213888.
MarketBeat Community Rating for Hutchison China MediTech (LON HCM)
MarketBeat's community ratings are surveys of what our community members think about Hutchison China MediTech and other stocks. Vote "Outperform" if you believe HCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
